Healthcare / BiotechnologyTokyo
$123.00
-5.00 (-3.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-203.9M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.7B
P/E
110.8x
↑EV/EBITDA
N/A
•ROE
1.1%
↑Gross Margin
55.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.1%
FCF CAGR
—
FCF margin
-3.0%
FCF / Net income
-0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.98B · net income $103.2M · FCF $-89.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.98B | $2.98B | $2.43B | $2.95B | $2.23B |
| Net Income | $103.2M | $103.2M | $-31.4M | $-305.3M | $-575.1M |
| EBITDA | $-79.7M | $-79.7M | $-372.2M | $-254.6M | $-513.8M |
| EPS | 1.11 | 1.11 | -0.37 | -3.62 | — |
| Gross Margin | 55.4% | 55.4% | 46.2% | 38.6% | 36.0% |
| Operating Margin | -4.4% | -4.4% | -16.9% | -12.1% | -29.0% |
| Net Margin | 3.5% | 3.5% | -1.3% | -10.3% | -25.7% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.01 |
| Current Ratio | 11.88 | 11.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-89.9M | $-89.9M | $-203.9M | $-301.6M | $-294.3M |
| Returns | |||||
| ROE | 1.1% | 1.1% | -0.4% | -4.0% | -7.9% |
| Valuation | |||||
| P/E | 110.81 | 110.81 | — | — | — |
| P/B | 1.27 | 1.27 | 1.52 | 2.50 | 2.55 |
| Growth & Yield | |||||
| Revenue Growth | 22.7% | 22.7% | -17.8% | 32.2% | — |
| EPS Growth | 400.0% | 400.0% | 89.8% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
114.2%
EPS terminal req.
$10.91
Spread vs growth
285.8%
5Y implied EPS CAGR
64.1%
EPS terminal req.
$13.21
Spread vs growth
335.9%
10Y implied EPS CAGR
34.4%
EPS terminal req.
$21.27
Spread vs growth
365.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.37 → 1.11
Residual
-27.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.